FY2026 EPS Estimates for Penumbra Decreased by Analyst

Penumbra, Inc. (NYSE:PEN - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2026 EPS estimates for shares of Penumbra in a note issued to investors on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of $5.53 per share for the year, down from their previous estimate of $5.54. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra's FY2027 earnings at $7.09 EPS, FY2028 earnings at $8.26 EPS and FY2029 earnings at $9.34 EPS.

PEN has been the subject of several other research reports. Canaccord Genuity Group increased their price objective on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Wells Fargo & Company raised their price objective on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a report on Thursday. Royal Bank of Canada lifted their price target on Penumbra from $315.00 to $330.00 and gave the company an "outperform" rating in a research note on Thursday. UBS Group reaffirmed a "buy" rating and issued a $330.00 price objective (up previously from $320.00) on shares of Penumbra in a research note on Thursday. Finally, StockNews.com upgraded shares of Penumbra from a "hold" rating to a "buy" rating in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $302.40.

Penumbra Price Performance

Shares of PEN stock traded up $2.25 on Friday, reaching $300.50. The company had a trading volume of 608,778 shares, compared to its average volume of 424,593. The business's 50-day moving average is $276.99 and its 200 day moving average is $255.22. Penumbra has a one year low of $148.00 and a one year high of $310.00. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $11.64 billion, a PE ratio of 883.82, a price-to-earnings-growth ratio of 2.83 and a beta of 0.56.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million.

Insider Activity

In related news, Director Thomas Wilder sold 360 shares of the business's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $264.58, for a total value of $95,248.80. Following the completion of the sale, the director now directly owns 4,533 shares of the company's stock, valued at $1,199,341.14. The trade was a 7.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Lambert Shiu sold 501 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $282.88, for a total value of $141,722.88. Following the completion of the transaction, the chief accounting officer now owns 32,969 shares in the company, valued at approximately $9,326,270.72. The trade was a 1.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 128,446 shares of company stock valued at $35,959,193 in the last ninety days. 5.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Penumbra

Several hedge funds and other institutional investors have recently modified their holdings of PEN. Barclays PLC increased its stake in Penumbra by 16.5% during the 3rd quarter. Barclays PLC now owns 18,025 shares of the company's stock valued at $3,502,000 after purchasing an additional 2,559 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Penumbra during the third quarter valued at about $367,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Penumbra during the third quarter worth about $6,995,000. Tidal Investments LLC raised its holdings in shares of Penumbra by 2.7% in the 3rd quarter. Tidal Investments LLC now owns 5,008 shares of the company's stock worth $973,000 after acquiring an additional 130 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Penumbra by 8.2% in the 3rd quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock valued at $67,473,000 after acquiring an additional 24,091 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.